Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, USA.
2Department of Medicine, Northwell Health Center for Liver Disease & Transplantation, North Shore, University Hospital/Northwell Health, 400 Community Drive, Manhasset, NY 11030, USA.
Curr Pharm Biotechnol. 2024;25(4):426-433. doi: 10.2174/1389201025666230915103052.
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions, and its growing prevalence is a serious concern worldwide, especially in Western countries. Researchers have pointed out several genetic mutations associated with NAFLD; however, the imbalance of the gut microbial community also plays a critical role in the progression of NAFLD. Due to the lack of approved medicine, probiotics gain special attention in controlling metabolic disorders like NAFLD. Among these probiotics, (a member of natural gut microflora) is considered one of the most efficient and important bacterium in maintaining gut health, energy homeostasis, and lipid metabolism. In this perspective, we discussed the probable molecular mechanism of A. muciniphila in controlling the progression of NAFLD and restoring liver health. The therapeutic potential of A. muciniphila in NAFLD has been tested primarily on animal models, and thus, more randomized human trials should be conducted to prove its efficacy.
非酒精性脂肪性肝病 (NAFLD) 是一系列肝脏疾病,其患病率不断上升,这是一个全球性的严重问题,尤其是在西方国家。研究人员已经指出了几种与 NAFLD 相关的基因突变;然而,肠道微生物群落的失衡也在 NAFLD 的进展中起着关键作用。由于缺乏批准的药物,益生菌在控制代谢紊乱方面引起了特别关注,如 NAFLD。在这些益生菌中,(一种天然肠道微生物群的成员)被认为是维持肠道健康、能量平衡和脂质代谢最有效和最重要的细菌之一。在这篇观点文章中,我们讨论了 A. muciniphila 控制 NAFLD 进展和恢复肝脏健康的可能分子机制。A. muciniphila 在 NAFLD 中的治疗潜力主要在动物模型中进行了测试,因此,应该进行更多的随机人体试验来证明其疗效。